These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 7657671

  • 1. Very low density lipoprotein receptor binds and mediates endocytosis of urokinase-type plasminogen activator-type-1 plasminogen activator inhibitor complex.
    Heegaard CW, Simonsen AC, Oka K, Kjøller L, Christensen A, Madsen B, Ellgaard L, Chan L, Andreasen PA.
    J Biol Chem; 1995 Sep 01; 270(35):20855-61. PubMed ID: 7657671
    [Abstract] [Full Text] [Related]

  • 2. Analysis of the binding of pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library.
    Horn IR, Moestrup SK, van den Berg BM, Pannekoek H, Nielsen MS, van Zonneveld AJ.
    J Biol Chem; 1995 May 19; 270(20):11770-5. PubMed ID: 7538122
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Fibrinolytic activity of human mesothelial cells is counteracted by rapid uptake of tissue-type plasminogen activator.
    Sitter T, Toet K, Quax P, Kooistra T.
    Kidney Int; 1999 Jan 19; 55(1):120-9. PubMed ID: 9893120
    [Abstract] [Full Text] [Related]

  • 5. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
    Rodenburg KW, Kjoller L, Petersen HH, Andreasen PA.
    Biochem J; 1998 Jan 01; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The very low density lipoprotein receptor mediates the cellular catabolism of lipoprotein lipase and urokinase-plasminogen activator inhibitor type I complexes.
    Argraves KM, Battey FD, MacCalman CD, McCrae KR, Gåfvels M, Kozarsky KF, Chappell DA, Strauss JF, Strickland DK.
    J Biol Chem; 1995 Nov 03; 270(44):26550-7. PubMed ID: 7592875
    [Abstract] [Full Text] [Related]

  • 10. gp330 on type II pneumocytes mediates endocytosis leading to degradation of pro-urokinase, plasminogen activator inhibitor-1 and urokinase-plasminogen activator inhibitor-1 complex.
    Stefansson S, Kounnas MZ, Henkin J, Mallampalli RK, Chappell DA, Strickland DK, Argraves WS.
    J Cell Sci; 1995 Jun 03; 108 ( Pt 6)():2361-8. PubMed ID: 7673355
    [Abstract] [Full Text] [Related]

  • 11. Receptor-mediated endocytosis of tissue-type plasminogen activator by low density lipoprotein receptor-related protein on human hepatoma HepG2 cells.
    Bu G, Maksymovitch EA, Schwartz AL.
    J Biol Chem; 1993 Jun 15; 268(17):13002-9. PubMed ID: 8389767
    [Abstract] [Full Text] [Related]

  • 12. Molecular analysis of ligand binding to the second cluster of complement-type repeats of the low density lipoprotein receptor-related protein. Evidence for an allosteric component in receptor-associated protein-mediated inhibition of ligand binding.
    Horn IR, van den Berg BM, van der Meijden PZ, Pannekoek H, van Zonneveld AJ.
    J Biol Chem; 1997 May 23; 272(21):13608-13. PubMed ID: 9153209
    [Abstract] [Full Text] [Related]

  • 13. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
    Skeldal S, Larsen JV, Pedersen KE, Petersen HH, Egelund R, Christensen A, Jensen JK, Gliemann J, Andreasen PA.
    FEBS J; 2006 Nov 23; 273(22):5143-59. PubMed ID: 17042782
    [Abstract] [Full Text] [Related]

  • 14. Functional domains of the very low density lipoprotein receptor: molecular analysis of ligand binding and acid-dependent ligand dissociation mechanisms.
    Mikhailenko I, Considine W, Argraves KM, Loukinov D, Hyman BT, Strickland DK.
    J Cell Sci; 1999 Oct 23; 112 ( Pt 19)():3269-81. PubMed ID: 10504332
    [Abstract] [Full Text] [Related]

  • 15. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas.
    Christensen L, Wiborg Simonsen AC, Heegaard CW, Moestrup SK, Andersen JA, Andreasen PA.
    Int J Cancer; 1996 May 16; 66(4):441-52. PubMed ID: 8635858
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cell cycle-dependent fluctuation of urokinase-type plasminogen activator, its receptor, and inhibitors in cultured bovine mammary epithelial and myoepithelial cells.
    Zavizion B, White JH, Bramley AJ.
    Biochim Biophys Acta; 1998 Jun 22; 1403(2):141-50. PubMed ID: 9630579
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The putative tumor suppressor LRP1B, a novel member of the low density lipoprotein (LDL) receptor family, exhibits both overlapping and distinct properties with the LDL receptor-related protein.
    Liu CX, Li Y, Obermoeller-McCormick LM, Schwartz AL, Bu G.
    J Biol Chem; 2001 Aug 03; 276(31):28889-96. PubMed ID: 11384978
    [Abstract] [Full Text] [Related]

  • 20. Differential endocytosis of tissue plasminogen activator by serpins PAI-1 and PAI-2 on human peripheral blood monocytes.
    Lee JA, Croucher DR, Ranson M.
    Thromb Haemost; 2010 Dec 03; 104(6):1133-42. PubMed ID: 20838737
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.